Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...

Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Lasell University president Eric Turner is hoping that many Lasell students will find success in the real world by spending ...

Beyond being a big deal for Takeda, which is the state’s largest life sciences employer and is relocating its Central Square ...